[ad_1]
Remdesivir has little or no effect on the likelihood that patients infected with the coronavirus will survive. This is demonstrated by an investigation by the World Health Organization, cited by the BBC.
Remdesivir is one of the first drugs since the beginning of the coronavirus pandemic. It was also prescribed for US President Donald Trump after he tested positive for the virus.
The tests included four drugs that are expected to help cope with the symptoms of COVID-19. Among them is hydrochloroquine.
The makers of the Gilead drug deny the results of the studies.
On October 14, the Bulgarian government announced that it would allocate BGN 2.1 million for the purchase of 2,500 vials of Remdesivir. The value of a vial of the drug is 345 euros without VAT, Health Minister Kostadin Angelov said at a briefing at the Council of Ministers.
So far, 2,837 vials of Remdesivir have been received and donated in Bulgaria. They are distributed to all sanitary inspections in the country. By October 12, 978 vials had been used.
The solidarity clinical trial
Six months after the onset of the pandemic, WHO and its partners are conducting a randomized clinical trial, Solidarity. The aim of the study was to identify possible effective treatments for COVID-19 that would slow the progression of the disease or improve the chances of survival.
These studies usually take a decade. However, due to the scale of the coronavirus pandemic, WHO is expanding the scope of testing. To ensure the most accurate results in a short time, a large number of participants from different countries are involved. The participants so far are more than 11,200 patients from 30 countries.
The results so far
Interim results showed that lopinavir / ritonavir, interferon, hydrochloroquine, and remdesivir did not have a significant positive effect on the 28-day mortality of coronavirus-infected patients or on the course of the disease in hospitalized patients.
Criteria that have been taken into account by health experts include overall mortality, change to mechanical ventilation, and length of hospital stay. However, they are only valid for hospital conditions and not for the free admission of patients who are treated from home.
At the end of the WHO trials, dexamethasone is currently the only drug approved for the treatment of COVID-19 that improves the chances of surviving the coronavirus. It is an inexpensive steroid that can be taken orally and is widespread throughout the world.
However, the WHO recommends that steroid treatment be used only in severe cases of coronavirus.
